Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638820 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity AlloTransplant For Osteopetrosis
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00638820 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 3 participants.
The verdict
NCT00638820, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
We believe that hematopoietic stem cell transplantation (HSCT) will help subjects with Osteopetrosis generate functioning osteoclasts, and by so doing assist in the resolution of the abnormal bone architecture, and the anemia and bone marrow failure that is also characteristic of this disease. However, we have found in past studies that approximately 30% of Osteopetrosis patients do not engraft. Therefore, in this study, we plan to use a different combination of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors. The purpose of this research is to find a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality.
Interventions
- PROCEDURE Stem Cell or Umbilical Cord Blood Transplantation
- DRUG Campath, Busulfan, Clofarabine
- PROCEDURE Total Lymphoid Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638820
The ClinicalTrials.gov registry entry for NCT00638820 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Stem Cell or Umbilical Cord Blood Transplantation is the first listed.
NCT00638820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638820 about?
NCT00638820 is a clinical study titled "Reduced Intensity AlloTransplant For Osteopetrosis". We believe that hematopoietic stem cell transplantation (HSCT) will help subjects with Osteopetrosis generate functioning osteoclasts, and by so doing assist in the resolution of the abnormal bone architecture, and the anemia and bone marrow failure that is also characteristic of this disease. Howev...
What is the current status of trial NCT00638820?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-09. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00638820?
The interventions under investigation include: Stem Cell or Umbilical Cord Blood Transplantation (PROCEDURE), Campath, Busulfan, Clofarabine (DRUG), Total Lymphoid Irradiation (PROCEDURE).
Who is sponsoring clinical trial NCT00638820?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.